Online inquiry

IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8016MR)

This product GTTS-WQ8016MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD52 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001803.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1043
UniProt ID P31358
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8016MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10366MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY2062430
GTTS-WQ2670MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 655
GTTS-WQ8934MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ2492MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ11382MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-573
GTTS-WQ13234MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ11182MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI0562
GTTS-WQ6050MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CNTO 136
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW